Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration

NCTID	NCT01494805 (View at clinicaltrials.gov)
Description	The study will involve approximately 40 subjects aged 55 or above who have exudative age-related macular degeneration (wet AMD). Patients will be randomized to receive one of two doses of rAAV.sFlt-1 or assigned to the control group. (Show More)
Development Status	Inactive
Indication	Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
Disease Ontology Term	DOID:10871
Compound Name	RAAV.sFlt-1
Compound Description	rAAV.CMV.sFlt-1
Sponsor	Lions Eye Institute, Perth, Western Australia
Funder Type	Other
Recruitment Status	Completed
Enrollment Count	40
Results Posted	Not Available

Target Gene/Variant	Soluble VEGFR1
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Genetic delivery of therapeutic protein
Route of Administration	Subretinal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV
Editor Type
Dose 1	1E10 vg (n=3)
Dose 2	1E11 vg (n=3)
Dose 3	1E11 vg (n=21)
Dose 4
Dose 5

No.of Trial Sites	1
Locations	Australia

Has US IND
FDA Designations
Recent Updates	Product was well tolerated, unable to determine efficacy